Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.33 |
| ▸ | WNT3A | P56704 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23636204 | 0.79 | RAB9A (0.40) | KMT2ALMNAL3MBTL1 | |
| SCHEMBL26304663 | 0.77 | L3MBTL1 (0.33) | KMT2AL3MBTL1 | |
| SCHEMBL10373456 | 0.64 | P2RX7 (0.52) | CTNNB1WNT3AKMT2ANAPRTCES2 | |
| SCHEMBL6633592 | 0.64 | NPSR1 (0.35) | KMT2ANAPRTCES2CES1LMNA | |
| SCHEMBL12462284 | 0.63 | NOS3 (0.35) | KMT2A | |
| SCHEMBL27938851 | 0.62 | MEN1 (0.30) | KMT2ALMNA | |
| SCHEMBL19675348 | 0.62 | ALDH1A1 (0.32) | KMT2AL3MBTL1 | |
| SCHEMBL2890937 | 0.62 | KMT2A (0.63) | CTNNB1WNT3AKMT2ANAPRTCES2 | |
| SCHEMBL24977120 | 0.60 | KMT2A (0.67) | KMT2ANAPRTCES2CES1LMNA | |
| SCHEMBL22406366 | 0.58 | LIG1 (0.52) | KMT2ANAPRTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11066421-B1 | Synthetic cinchona alkaloids against cancer | Ares Pharmaceuticals, LLC (US) | 2021-07-20 | — | — | US | claimed |
| US-11066421-B1 | Synthetic cinchona alkaloids against cancer | Ares Pharmaceuticals, LLC (US) | 2021-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066421-B1 | Synthetic cinchona alkaloids against cancer | UACA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GDA | CTNNB1 3840/4885WNT3A 3595/4885KMT2A 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.